|
1
|
Spira A and Ettinger DS: Multidisciplinary
management of lung cancer. N Engl J Med. 350:379–392. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Govindan R, Page N, Morgensztern D, Read
W, Tierney R, Vlahiotis A, Spitznagel EL and Piccirillo J: Changing
epidemiology of small-cell lung cancer in the United States over
the last 30 years: Analysis of the surveillance, epidemiologic, and
end results database. J Clin Oncol. 24:4539–4544. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sun S, Schiller JH, Spinola M and Minna
JD: New molecularly targeted therapies for lung cancer. J Clin
Invest. 117:2740–2750. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jemal A, Siegel R, Ward E, Murray T, Xu J,
Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin.
56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
de Mello RA, Madureira P, Carvalho LS,
Araújo A, O'Brien M and Popat S: EGFR and KRAS mutations, and ALK
fusions: Current developments and personalized therapies for
patients with advanced non-small-cell lung cancer.
Pharmacogenomics. 14:1765–1777. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wagner G, Stollenwerk HK, Klerings I,
Pecherstorfer M, Gartlehner G and Singer J: Efficacy and safety of
immune checkpoint inhibitors in patients with advanced non-small
cell lung cancer (NSCLC): A systematic literature review.
Oncoimmunology. 9:17743142020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gaddy-Kurten D, Tsuchida K and Vale W:
Activins and the receptor serine kinase superfamily. Recent Prog
Horm Res. 50:109–129. 1995.PubMed/NCBI
|
|
8
|
Loomans HA and Andl CD: Intertwining of
activin A and TGFβ signaling: Dual roles in cancer progression and
cancer cell invasion. Cancers (Basel). 7:70–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Green JB, New HV and Smith JC: Responses
of embryonic xenopus cells to activin and FGF are separated by
multiple dose thresholds and correspond to distinct axes of the
mesoderm. Cell. 71:731–739. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vale W, Rivier C, Hsueh A, Campen C,
Meunier H, Bicsak T, Vaughan J, Corrigan A, Bardin W, Sawchenko P,
et al: Chemical and biological characterization of the inhibin
family of protein hormones. Recent Prog Horm Res. 44:1–34.
1988.PubMed/NCBI
|
|
11
|
Kelner N, Rodrigues PC, Bufalino A,
Fonseca FP, Santos-Silva AR, Miguel MC, Pinto CA, Leme AF, Graner
E, Salo T, et al: Activin A immunoexpression as predictor of occult
lymph node metastasis and overall survival in oral tongue squamous
cell carcinoma. Head Neck. 37:479–486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fu S, Zhang N, Yopp AC, Chen D, Mao M,
Chen D, Zhang H, Ding Y and Bromberg JS: TGF-beta induces Foxp3 +
T-regulatory cells from CD4 + CD25-precursors. Am J Transplant.
4:1614–1627. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ogawa K and Funaba M: Activin in humoral
immune responses. Vitam Horm. 85:235–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Q, Wen YG, Li DP, Xia J, Zhou CZ, Yan
DW, Tang HM and Peng ZH: Upregulated INHBA expression is associated
with poor survival in gastric cancer. Med Oncol. 29:77–83. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee HY, Li CC, Huang CN, Li WM, Yeh HC, Ke
HL, Yang KF, Liang PI, Li CF and Wu WJ: INHBA overexpression
indicates poor prognosis in urothelial carcinoma of urinary bladder
and upper tract. J Surg Oncol. 111:414–422. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Peng S, Wang J, Hu P, Zhang W, Li H and Xu
L: INHBA knockdown inhibits proliferation and invasion of
nasopharyngeal carcinoma SUNE1 cells in vitro. Int J Clin Exp
Pathol. 13:854–868. 2020.PubMed/NCBI
|
|
17
|
Seder CW, Hartojo W, Lin L, Silvers AL,
Wang Z, Thomas DG, Giordano TJ, Chen G, Chang AC, Orringer MB and
Beer DG: Upregulated INHBA expression may promote cell
proliferation and is associated with poor survival in lung
adenocarcinoma. Neoplasia. 11:388–396. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wamsley JJ, Kumar M, Allison DF, Clift SH,
Holzknecht CM, Szymura SJ, Hoang SA, Xu X, Moskaluk CA, Jones DR,
et al: Activin upregulation by NF-κB is required to maintain
mesenchymal features of cancer stem-like cells in non-small cell
lung cancer. Cancer Res. 75:426–435. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Varelas X, Samavarchi-Tehrani P, Narimatsu
M, Weiss A, Cockburn K, Larsen BG, Rossant J and Wrana JL: The
Crumbs complex couples cell density sensing to Hippo-dependent
control of the TGF-β-SMAD pathway. Dev Cell. 19:831–844. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Narimatsu M, Samavarchi-Tehrani P, Varelas
X and Wrana JL: Distinct polarity cues direct Taz/Yap and TGFβ
receptor localization to differentially control TGFβ-induced smad
signaling. Dev Cell. 32:652–656. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fujii M, Toyoda T, Nakanishi H, Yatabe Y,
Sato A, Matsudaira Y, Ito H, Murakami H, Kondo Y, Kondo E, et al:
TGF-β synergizes with defects in the Hippo pathway to stimulate
human malignant mesothelioma growth. J Exp Med. 209:479–494. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang J, Wu S, Barrera J, Matthews K and
Pan D: The Hippo signaling pathway coordinately regulates cell
proliferation and apoptosis by inactivating yorkie, the drosophila
homolog of YAP. Cell. 122:421–434. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Edgar BA: From cell structure to
transcription: Hippo forges a new path. Cell. 124:267–273. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pan D: The Hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han Q, Lin X, Zhang X, Jiang G, Zhang Y,
Miao Y, Rong X, Zheng X, Han Y, Han X, et al: WWC3 regulates the
Wnt and Hippo pathways via dishevelled proteins and large tumour
suppressor 1, to suppress lung cancer invasion and metastasis. J
Pathol. 242:435–447. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: Introduction to the 2015 World Health
Organization classification of tumors of the lung, pleura, thymus,
and heart. J Thorac Oncol. 10:1240–1242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sobin LH, Gospodarowicz MK and Christian
Wittekind C: International Union Against Cancer (UICC): TNM
classification of malignant tumours. 8th edition. Oxford:
Wiley-Blackwell; 2017
|
|
28
|
Zhang Y, Zhao Y, Jiang G, Zhang X, Zhao H,
Wu J, Xu K and Wang E: Impact of p120-catenin isoforms 1A and 3A on
epithelial mesenchymal transition of lung cancer cells expressing
E-cadherin in different subcellular locations. PLoS One.
9:e880642014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Y, Yan S, Chen J, Gan C, Chen D, Li
Y, Wen J, Kremerskothen J, Chen S, Zhang J and Cao Y: WWC2 is an
independent prognostic factor and prevents invasion via Hippo
signalling in hepatocellular carcinoma. J Cell Mol Med.
21:3718–3729. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y, Dong Q, Zhang Q, Li Z, Wang E and
Qiu X: Overexpression of yes-associated protein contributes to
progression and poor prognosis of non-small-cell lung cancer.
Cancer Sci. 101:1279–1285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun PL, Kim JE, Yoo SB, Kim H, Jin Y,
Jheon S, Kim K, Lee CT and Chung JH: Cytoplasmic YAP expression is
associated with prolonged survival in patients with lung
adenocarcinomas and epidermal growth factor receptor tyrosine
kinase inhibitor treatment. Ann Surg Oncol. 21 (Suppl 4):S610–S618.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Su T, Ludwig MZ, Xu J and Fehon RG: Kibra
and Merlin activate the Hippo pathway spatially distinct from and
independent of expanded. Dev Cell. 40:478–490.e3. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Alcantara KMM and Garcia RL: MicroRNA-92a
promotes cell proliferation, migration and survival by directly
targeting the tumor suppressor gene NF2 in colorectal and lung
cancer cells. Oncol Rep. 41:2103–2116. 2019.PubMed/NCBI
|
|
35
|
Sánchez NC, Medrano-Jiménez E,
Aguilar-León D, Pérez-Martínez L and Pedraza-Alva G: Tumor necrosis
factor-induced miR-146a upregulation promotes human lung
adenocarcinoma metastasis by targeting Merlin. DNA Cell Biol.
39:484–497. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wei Y, Yee PP, Liu Z, Zhang L, Guo H,
Zheng H, Anderson B, Gulley M and Li W: NEDD4L-mediated Merlin
ubiquitination facilitates Hippo pathway activation. EMBO Rep.
21:e506422020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tang X, Jang SW, Wang X, Liu Z, Bahr SM,
Sun SY, Brat D, Gutmann DH and Ye K: Akt phosphorylation regulates
the tumour-suppressor Merlin through ubiquitination and
degradation. Nat Cell Biol. 9:1199–1207. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mota MSV, Jackson WP, Bailey SK, Vayalil
P, Landar A, Rostas JW III, Mulekar MS, Samant RS and Shevde LA:
Deficiency of tumor suppressor Merlin facilitates metabolic
adaptation by co-operative engagement of SMAD-Hippo signaling in
breast cancer. Carcinogenesis. 39:1165–1175. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kavsak P, Rasmussen RK, Causing CG, Bonni
S, Zhu H, Thomsen GH and Wrana JL: Smad7 binds to Smurf2 to form an
E3 ubiquitin ligase that targets the TGF beta receptor for
degradation. Mol Cell. 6:1365–1375. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang Z, Liu C, Chen B, Tang W, Liu Z, Cao
W and Li X: Smad7 down-regulation via ubiquitin degradation
mediated by Smurf2 in fibroblasts of hypertrophic scars in burned
patients. Burns. 47:1333–1341. 2021. View Article : Google Scholar : PubMed/NCBI
|
